Phase II Validation of a New Panel of Biomarkers for Early Detection of Ovarian Cancer
- Abbreviated Name
- Ovarian Validation Study - Mor
- Lead Investigator
- Mor, Gil — Yale University
- Coordinating Investigator
- Zheng, Yingye — Fred Hutchinson Cancer Center
- Involved Investigators
-
- Godwin, Andrew K — University of Kansas Medical Center
- Lokshin, Anna — University of Pittsburgh Cancer Institute
- Srivastava, Sudhir — National Cancer Institute
- Birrer, Michael — University of Arkansas for Medical Sciences
- Aparicio, Belen — Instituto Valenciano de Infertilidad
- Valcour, Andre — Lab Corps
- Steffensen, Karina Dahl — Vejle Hospital
- Mor, Gil — Yale University
- Kalloger, Steve E. — Kalloger Consulting
- Zheng, Yingye — Fred Hutchinson Cancer Center
Abstract
While all cancer patients could potentially benefit from earlier detection and prevention, the development of new screening technologies and chemoprevention for epithelial ovarian cancer (EOC) is unique in this regard. EOC is characterized by few early symptoms, presentation at an advanced stage, and poor survival. Presently there is no commercially available test that is diagnostic for either early or advanced stage epithelial ovarian cancer. The most commonly used marker, CA125, identifies a group of cell surface glycoproteins, which have uncertain biological behavior and very limited clinical utility for the detection of early stage disease. In recent years, several approaches have been used in order to develop a test for early detection, including the analysis of serum samples by SELDI-TOF and MALDI-TOF to find proteins or protein fragments of unknown identity that detect the presence/absence of cancer. Unfortunately, at the present time, none of these techniques have been shown to be adequate. Therefore, the development of a test that can detect early stages of the disease could dramatically improve treatment success and long-term survival. We have developed a new blood test based on a different approach: 1) we used known proteins related to cancer biology, 2) we characterized these proteins with several different screening steps using samples obtained from both healthy and cancer patient populations, and 3) validated the results with different techniques. Using split point analysis with four markers, 96 out of 100 EOC patients (96%) were correctly diagnosed with ovarian cancer (including 23 of 24 patients with Stage I/II EOC). In the healthy group, 6 out of 106 individuals were diagnosed incorrectly (5.6%). Working in collaboration with the Early Detection Network (EDRN/NCI/NIH), we performed Phase I discovery study confirming the potential application of this test for early detection of ovarian cancer (Preliminary results). The main objective of this pr
Aims
Aim 1. To validate the Yale Early Detection Assay (YEDA) in a Phase II Validation Trial consisting of a case control study for patients with ovarian cancer. Aim 2. To determine whether the Luminex platform and the inclusion of three additional markers will increase the sensitivity and specificity of the test.
Analytic Method
The concentration of the four markers will be measured in the serum using a sandwich ELISA. For the Phase II validation study all the tests will be performed by LabCorp, which has completed the process of validation and standardization of the four analytes. The Luminex platform will be evaluated at Yale. The specimen will be blinded to all labs on disease status. The blinded labels will be provided by EDRN/DMCC. The assay data will be sent to EDRN/DMCC.
Outcome
While all cancer patients could potentially benefit from earlier detection and prevention, the development of new screening technologies and chemoprevention for epithelial ovarian cancer (EOC) is unique in this regard. EOC is characterized by few early symptoms, presentation at an advanced stage, and poor survival. Presently there is no commercially available test that is diagnostic for either early or advanced stage epithelial ovarian cancer. The most commonly used marker, CA125, identifies a group of cell surface glycoproteins, which have uncertain biological behavior and very limited clinical utility for the detection of early stage disease. In recent years, several approaches have been used in order to develop a test for early detection, including the analysis of serum samples by SELDI-TOF and MALDI-TOF to find proteins or protein fragments of unknown identity that detect the presence/absence of cancer. Unfortunately, at the present time, none of these techniques have been shown to be adequate. Therefore, the development of a test that can detect early stages of the disease could dramatically improve treatment success and long-term survival. We have developed a new blood test based on a different approach: 1) we used known proteins related to cancer biology, 2) we characterized these proteins with several different screening steps using samples obtained from both healthy and cancer patient populations, and 3) validated the results with different techniques. Using split point analysis with four markers, 96 out of 100 EOC patients (96%) were correctly diagnosed with ovarian cancer (including 23 of 24 patients with Stage I/II EOC). In the healthy group, 6 out of 106 individuals were diagnosed incorrectly (5.6%). Working in collaboration with the Early Detection Network (EDRN/NCI/NIH), we performed Phase I discovery study confirming the potential application of this test for early detection of ovarian cancer (Preliminary results). The main objective of this pr
Publications
Biomarkers
Data Collections
- No data collections available at this time for this protocol.
- Start Date
- May 1 2008
- Estimated Finish Date
- Nov 1 2008
- Finish Date
- Jun 11 2008
- Protocol ID
- 244
- Protocol Type
- Validation
- Fields of Research
-
- Proteomics
- Collaborative Group
- Breast and Gynecologic Cancers Research Group
- Cancer Types
-
- Malignant neoplasm of ovary
- Phased Status
- 2